Literature DB >> 26837242

Induction of protective neutralizing antibody responses against botulinum neurotoxin serotype C using plasmid carried by PLGA nanoparticles.

Tinashe B Ruwona1, Haiyue Xu1, Junwei Li2, Diana Diaz-Arévalo2, Amit Kumar1, Mingtao Zeng2, Zhengrong Cui1.   

Abstract

Botulinum neurotoxin (BoNT) is a lethal neurotoxin, for which there is currently not an approved vaccine. Recent efforts in developing vaccine candidates against botulism have been directed at the heavy chain fragment of BoNT, because antibodies against this region have been shown to prevent BoNT from binding to its receptor and thus to nerve cell surface, offering protection against BoNT intoxication. In the present study, it was shown that immunization with plasmid DNA that encodes the 50 KDa C-terminal fragment of the heavy chain of BoNT serotype C (i.e., BoNT/C-Hc50) and is carried by cationic poly (lactic-co-glycolic) acid (PLGA) nanoparticles induces stronger BoNT/C-specific antibody responses, as compared to immunization with the plasmid alone. Importantly, the antibodies have BoNT/C-neutralizing activity, protecting the immunized mice from a lethal dose of BoNT/C challenge. A plasmid DNA vaccine encoding the Hc50 fragments of BoNT serotypes that cause human botulism may represent a viable vaccine candidate for protecting against botulinum neurotoxin intoxication.

Entities:  

Keywords:  PLGA nanoparticles; antibody responses; botulinum neurotoxin; mouse survival

Mesh:

Substances:

Year:  2016        PMID: 26837242      PMCID: PMC4963044          DOI: 10.1080/21645515.2015.1122147

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  33 in total

1.  DNA vaccination protects against botulinum neurotoxin type F.

Authors:  Alice M Bennett; Stuart D Perkins; Jane L Holley
Journal:  Vaccine       Date:  2003-07-04       Impact factor: 3.641

2.  Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization.

Authors:  T J Smith; J Lou; I N Geren; C M Forsyth; R Tsai; S L Laporte; W H Tepp; M Bradshaw; E A Johnson; L A Smith; J D Marks
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

3.  Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins.

Authors:  Robert P Webb; Theresa J Smith; Patrick M Wright; Vicki A Montgomery; Michael M Meagher; Leonard A Smith
Journal:  Vaccine       Date:  2007-03-16       Impact factor: 3.641

4.  Production and purification of the heavy-chain fragment C of botulinum neurotoxin, serotype B, expressed in the methylotrophic yeast Pichia pastoris.

Authors:  K J Potter; M A Bevins; E V Vassilieva; V R Chiruvolu; T Smith; L A Smith; M M Meagher
Journal:  Protein Expr Purif       Date:  1998-08       Impact factor: 1.650

Review 5.  Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins.

Authors:  M Z Atassi; M Oshima
Journal:  Crit Rev Immunol       Date:  1999       Impact factor: 2.214

Review 6.  DNA vaccines: an historical perspective and view to the future.

Authors:  Margaret A Liu
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

7.  Towards preserving the immunogenicity of protein antigens carried by nanoparticles while avoiding the cold chain.

Authors:  Brian R Sloat; Michael A Sandoval; Zhengrong Cui
Journal:  Int J Pharm       Date:  2010-04-21       Impact factor: 5.875

8.  Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine.

Authors:  Mingtao Zeng; Qingfu Xu; Md Elias; Michael E Pichichero; Lance L Simpson; Leonard A Smith
Journal:  Vaccine       Date:  2007-09-05       Impact factor: 3.641

9.  Microneedle-mediated transcutaneous immunization with plasmid DNA coated on cationic PLGA nanoparticles.

Authors:  Amit Kumar; Piyanuch Wonganan; Michael A Sandoval; Xinran Li; Saijie Zhu; Zhengrong Cui
Journal:  J Control Release       Date:  2012-08-19       Impact factor: 9.776

10.  A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins.

Authors:  Jason R Barash; Stephen S Arnon
Journal:  J Infect Dis       Date:  2013-10-07       Impact factor: 5.226

View more
  1 in total

Review 1.  Nanobiotics against antimicrobial resistance: harnessing the power of nanoscale materials and technologies.

Authors:  Nayanika Chakraborty; Diksha Jha; Indrajit Roy; Pradeep Kumar; Shailendra Singh Gaurav; Kalisvar Marimuthu; Oon-Tek Ng; Rajamani Lakshminarayanan; Navin Kumar Verma; Hemant K Gautam
Journal:  J Nanobiotechnology       Date:  2022-08-12       Impact factor: 9.429

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.